Valantine Hannah 4

What Happened
Director Hannah Valantine exercised stock options to acquire a total of 28,779 CareDx (CDNA) shares on 2026-07-16 (three tranches) and sold the same 28,779 shares in open-market transactions that day. The exercises cost a total of $424,895 (7,606 @ $20.56 = $156,379; 16,048 @ $14.19 = $227,721; 5,125 @ $7.96 = $40,795). The subsequent sales produced total proceeds of approximately $1,040,243 (28,679 shares at a weighted average $36.14 = $1,036,588; 100 shares @ $36.55 = $3,655).

Key Details

• Transaction date: 2026-07-16; Form filed 2026-07-17 (timely).
• Exercise details: 7,606 / 16,048 / 5,125 shares at $20.56, $14.19, $7.96 respectively; option reported as fully vested (F3).
• Sales: 28,779 shares sold the same day; weighted average reported $36.14 (range $35.55–$36.50) (F2).
• Reported proceeds from sales: ~$1,040,243; aggregate exercise cost: $424,895.
• Footnote: Sales were effected under a Rule 10b5-1 trading plan adopted December 11, 2025 (F1).
• Shares owned after the transactions are not specified in the supplied filing.

Context
This was an exercise of vested options followed by immediate sale of the exercised shares (a cashless-style outcome). The reporting notes the sales were executed under a pre-established 10b5-1 plan, which typically indicates scheduled, non-discretionary sales rather than ad hoc insider selling. The filing appears timely (filed the day after the reported transactions).